Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond

Chim, C S, Kumar, S K, Orlowski, R Z, Cook, G, Richardson, P G, Gertz, M A, Giralt, S, Mateos, M V, Leleu, X, Anderson, K C·2018·Leukemia
DOI 10.1038/leu.2017.329

Cited by (305)

Items 201–300 of 305

  1. Pan-cancer analysis of co-inhibitory molecules revealing their potential prognostic and clinical values in immunotherapy
    Xiaoyu Ren, Anjie Guo, Jiahui Geng, Yuling Chen, Xue Wang, Lian Zhou, Lei Shi · 2025 · Frontiers in Immunology
  2. Monoclonal Antibodies and Multiple Myeloma: All in All It's Just Another Brick in the Wall?
    Pellegrino Musto · 2018 · The Oncologist
  3. Daratumumab Interference in Flow Cytometry Producing a False Kappa Light Chain Restriction in Plasma Cells
    William Kleinot, Nadine S. Ives Aguilera, Elizabeth L. Courville · 2020 · Laboratory Medicine
  4. Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study
    Maria Livia Del Giudice, Alessandro Gozzetti, Elisabetta Antonioli, Enrico Orciuolo, Francesco Ghio, Sara Ciofini, Veronica Candi, Giulia Fontanelli, Irene Attucci, Giuseppe Formica et al. · 2021 · Medicina
  5. Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
    Xiangmin Wang, Bin Pan, He Huang, Kailin Xu · 2021 · ImmunoMedicine
  6. Treatment of elderly patients with refractory/relapsed multiple myeloma: oral drugs adherence and the COVID-19 outbreak
    Flávia Dias Xavier, Fernando Sérgio Blumm Ferreira, Rodrigo Martins Abreu · 2020 · Oncotarget
  7. Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study)
    Pellegrino Musto, Vittorio Simeon, Nicola Cascavilla, Antonietta Pia Falcone, Maria Teresa Petrucci, Laura Cesini, Francesco Di Raimondo, Concetta Conticello, Roberto Ria, Lucio Catalano et al. · 2018 · Annals of Hematology
  8. Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma
    Sophia Stock, Luisa Fertig, Adrian Gottschlich, Janina Dörr, Florian Märkl, Lina Majed, Vivien Doreen Menkhoff, Ruth Grünmeier, Kai Rejeski, David M. Cordas dos Santos et al. · 2024 · Cancer Immunology Immunotherapy
  9. Carfilzomib’s Real-World Safety Outcomes in Korea: Target Trial Emulation Study Using Electronic Health Records
    Ha Young Jang, Hyun Kyung Lee, Chae Jeong Kim, Sung‐Soo Yoon, In‐Wha Kim, Jung Mi Oh · 2022 · International Journal of Environmental Research and Public Health
  10. Unraveling innovation potential in the real-world setting: eighteen novel agents with twenty-six approved European indications, in the management of leukemias, lymphomas, and multiple myeloma
    Ioannis E Petrakis, Christos A. Kontogiorgis, Evangelia Nena, Kostas Athanasakis, Vasiliki Gougoula, Ιoannis Kotsianidis, Theodoros C. Constantinidis · 2019 · Expert Review of Hematology
  11. Daratumumab Monotherapy for Heavily Pre-treated and Refractory Myeloma: Results from a UK Multicentre Real World Cohort
    Nadjoua Maouche, Anandagopal Srinivasan, Heather Leary, Freya Collings, Bing Tseu, Grant D. Vallance, Karthik Ramasamy, Jaimal Kothari · 2021 · Journal of Oncology Pharmacy Practice
  12. Immunoproteasome Activity in Chronic Lymphocytic Leukemia as a Target of the Immunoproteasome-Selective Inhibitors
    Andrej Bešše, Marianne Kraus, Max Alberto Mendez-Lopez, Elmer Maurits, Herman S. Overkleeft, Christoph Driessen, Lenka Bešše · 2022 · Cells
  13. Post Salvage Therapy Autologous Transplant for Relapsed Myeloma, Ongoing Relevance within Modern Treatment Paradigms?
    Sahar Khan, Donna Ellen Reece, Eshetu G. Atenafu, Sita Bhella, Christine I. Chen, Esther Masih‐Khan, Harminder K Paul, Anca A. Prica, Rodger Edwin Tiedemann, Suzanne Trudel et al. · 2022 · Clinical Lymphoma Myeloma & Leukemia
  14. Novel cuproptosis-related lncRNAs can predict the prognosis of patients with multiple myeloma
    Yuying Chen, Jialin Tang, Lin Chen, Jianbin Chen · 2023 · Translational Cancer Research
  15. Evaluation of double heptamer-type sgRNA as a potential therapeutic agent against multiple myeloma
    Tatsuya Ishikawa, Arisa Haino, Takashi Ichiyanagi, Mineaki Seki, Masayuki Nashimoto · 2019 · Blood Cells Molecules and Diseases
  16. Chemotherapie von Tumorerkrankungen
    Michael Freissmuth · 2020 · Springer eBooks
  17. Challenges in Multiple Myeloma Therapy in Older and Frail Patients
    Anna Aureli, Beatrice Marziani, Tommaso Sconocchia, Gianmario Pasqualone, Luca Franceschini, Giulio C. Spagnoli, Adriano Venditti, Giuseppe Sconocchia · 2025 · Cancers
  18. Using artificial intelligence tools in answering important clinical questions: The KEYNOTE-183 multiple myeloma experience
    Jason J. Z. Liao, Mohammed Z.H. Farooqui, Patricia Maria Marinello, Jonathan S. Hartzel, Keaven M. Anderson, Junshui Ma, Christine K. Gause · 2020 · Contemporary Clinical Trials
  19. 3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma
    Chor Sang Chim, Shaji Kunnathu Kumar, Vincent Kai Chung Wong, Cheong Ngai, Yok‐Lam Kwong · 2021 · Hematology
  20. Comparison of health care costs and resource utilization for commonly used proteasome inhibitor–immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States
    Larysa Jessica Sanchez, Ajai Chari, Mu Cheng, Dasha Cherepanov, Maral DerSarkissian, Fei Huang, Dawn Marie Stull, Jonathan Dabora, Melanie Young, Stephen Joseph Noga et al. · 2023 · Journal of Managed Care & Specialty Pharmacy
  21. Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status
    David L. Baker, Milan Bimali, Luis F. Carrillo, Archana Sachedina, Daisy V. Alapat, Md Shadiqul Hoque, Mathew J. Kottarathara, Richa Parikh, Amani Erra, Angel A. Mitma et al. · 2021 · Haematologica
  22. Heptamer-type small guide RNA that can shift macrophages toward the M1 state
    Tatsuya Ishikawa, Arisa Haino, Takashi Ichiyanagi, Masayuki Takahashi, Mineaki Seki, Masayuki Nashimoto · 2020 · Blood Cells Molecules and Diseases
  23. Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma
    Linda Heimberg, Stefan Tobias Knop · 2021 · Oncology Research and Treatment
  24. Outcomes of triple-class refractory multiple myeloma patients at a single clinic: A retrospective study.
    Ryan Danis, S. Bujarski, David Yashar, Ashley Del Dosso, Jonathan Moore, Sarah Mettias, James R. Berenson · 2025 · Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis
  25. Renal Failure Due to Multiple Myeloma
    Adil Shaik, Terry L Oroszi · 2025 · Open Journal of Nephrology
  26. Efficacy of ixazomib-lenalidomide-dexamethasone in high-molecular-risk relapsed/refractory multiple myeloma – case series and literature review
    Aneta Szudy‐Szczyrek, Sylwia Chocholska, Oliwia Bachanek-Mitura, Olga Czabak, Radosław Mlak, Michał Szczyrek, Justyna Muzyka-Kasietczuk, Marek Hus · 2021 · Annals of Agricultural and Environmental Medicine
  27. Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study
    Tadao Ishida, Shigeki Ito, Junji Tanaka, Michihiro Uchiyama, Yawara Kawano, Philippe Moreau, Thomas G. Martin, Marie‐Laure Risse, Keisuke Tada, Kenshi Suzuki et al. · 2022 · Japanese Journal of Clinical Oncology
  28. Optimal timing of treatment at relapse after autologous stem cell transplantation in patients with multiple myeloma: a study of the Korean Multiple Myeloma Working Party (KMM-1909)
    Sung‐Hoon Jung, Chang‐Ki Min, Jae Hoon Lee, Yeung‐Chul Mun, Soo-Mee Bang, Dok Hyun Yoon, Ho Sup Lee, Kihyun Kım, Je‐Jung Lee · 2022 · Bone Marrow Transplantation
  29. Safety and Effectiveness of Elotuzumab in Japanese Patients with Relapsed/Refractory Multiple Myeloma: A Post-marketing Surveillance Study
    Fumiya Kaneko, Hiroshi Suzuka, Tomoaki Yoshino, Ryosuke Hinosugi · 2024 · Internal Medicine
  30. Safety and Effectiveness of Ixazomib Dose-escalating Strategy in Ixazomib-Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma
    Yasukata Ohashi, Megumi Yatabe, DAISUKE NIIJIMA, Kentaro Tani, Chiaki Ogawa, Yutaka Yachi, Toshiya Kagoo, Saigen Boku, HIRONORI UENO, Takahiro Yano et al. · 2020 · In Vivo
  31. How to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in Myeloma
    Treen C. M. Morris, Mary B. Drake, Paul J. Kettle, Tracey McGuigan, Maeve Leahy, Michael E O'Dwyer, H Enright, Tanya O’Shea, Rakesh Popat, Heather E. Oakervee et al. · 2021 · Clinical Hematology International
  32. MAPK Cascade Signaling Is Involved in α-MMC Induced Growth Inhibition of Multiple Myeloma MM.1S Cells via G2 Arrest and Mitochondrial-Pathway-Dependent Apoptosis In Vitro
    Ziwei Cai, Ting Ye, Pei-Wen Jiang, Yujiao Liao, Lin Wang, Qing-Liang Zhang, Wen-Qian Du, Min Huang, Ping Chang Yang, M Li · 2023 · Pharmaceuticals
  33. Health-Related Quality of Life and Treatment Satisfaction of Patients with Blood Cancer in Kazakhstan: A Cross-Sectional Study
    Атабаева А.К., Gulzat Z. Sarsenbayeva, Saule Maukayeva, Maria Anartaeva, Zaituna A. Khismetova, Оxana Tsigengagel · 2023 · Asian Pacific Journal of Cancer Prevention
  34. Novel anti-CD38 humanized mAb SG003 possessed enhanced cytotoxicity in lymphoma than Daratumumab via antibody-dependent cell-mediated cytotoxicity
    Tao Yu, Chunxia Qiao, Ming Lv, Luqun Tang · 2019 · BMC Biotechnology
  35. Monoclonal antibody utilization characteristics in patients with multiple myeloma
    Sikander Ailawadhi, Taimur Sher, Abdel‐Ghani Azzouqa, Zahara Meghji, Tania Jain, Prachi Jani, Salman Ahmed, Nancy N. Diehl, Vivek Roy, Vishal S. Shah et al. · 2019 · Anti-Cancer Drugs
  36. Blockade of PLD1 potentiates the antitumor effects of bortezomib in multiple myeloma cells by inhibiting the mTOR/NF-κB signal pathway
    Yanfang Wang, Fei Dong, Wei Wan, Zhenghao Zhang, Jing Wang, Hua Wang, Xiaoyan Ke · 2020 · Hematology
  37. Treatment Approaches of Multiple Myeloma
    Minyahil Alebachew Woldu, Atalay Mulu Fentie, Tamrat Assefa Tadesse · 2021 · IntechOpen eBooks
  38. Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial
    Wei Yee Chan, Nicholas Counsell, Ruth Mary De Tute, Dunnya De‐Silva, Elizabeth H. Phillips, Jamie D. Cavenagh, Toyin Adedayo, Nivette Braganca, Claire Roddie, Matthew J. Streetly et al. · 2021 · British Journal of Haematology
  39. Managing multiple myeloma in a resource-limited region: Diagnosis and treatment in Armenia
    Artem Oganesyan, Nerses Ghahramanyan, Arsène MEKINIAN, Nelli Bejanyan, Dickran Gano Kazandjian, Yervand K. Hakobyan · 2021 · Seminars in Oncology
  40. Current status of drug development for patients with multiple myeloma: a review of comparison in China and the rest of world
    Lei Huang, Jingyu Zhang, Elizabeth A. Punnoose, Zhenyu Xiao, Wenjin Li · 2023 · Antibody Therapeutics
  41. Does the Simultaneous Introduction of Several Pharmaceuticals in the Post-Lenalidomide Era Translate to Better Outcomes in Relapse Refractory Multiple Myeloma? Findings from the Real-World Innovation in Multiple Myeloma (REAL IMM) Study
    Ioannis E Petrakis, Christos A. Kontogiorgis, Evangelia Nena, Sosana Delimpasi, Natasa‐Eleni Loutsidi, Emmanouil Spanoudakis, Stergios Intzes, Christina Misidou, Marianthi Symeonidou, Nikolaos C. Giannakoulas et al. · 2023 · Cancers
  42. Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy
    Concetta Conticello, Vittorio Del Fabro, Alessandra Romano, Anna Mele, Roberto Mina, Sara Bringhen, Alessandra Orofino, Elisabetta Antonioli, Stefano Pulini, Lorenzo De Paoli et al. · 2025 · Annals of Hematology
  43. Optimising Treatment in Relapsed, Refractory Multiple Myeloma
    Monique C. Minnema, Maria Gavriatopoulou · 2018 · European Oncology & Haematology
  44. Extramedullary relapse of multiple myeloma presenting as a breast lump
    Dale Seviar, Zainab AlshiekhAli, David Crispin Howlett · 2021 · BMJ Case Reports
  45. Chimeric Antigen Receptor T-Cell Therapeutics for Multiple Myeloma
    Bo Wang, Sridevi Rajeeve, Deepu Madduri · 2021 · The Cancer Journal
  46. The dual role of Natural Killer cells during tumor progression and angiogenesis: Implications for tumor microenvironment-targeted immunotherapies
    Lorenzo Mortara, Denisa Baci, Grace Coco, Alessandro Delli Poggi, Antonino Bruno · 2021 · Elsevier eBooks
  47. Effect of Daratumumab combined with Chemotherapy on Immune Function in Patients with Relapsed/Refractory Multiple Myeloma and Observation of its Clinical Efficacy
    Yehua Zhang, Feng Xu, Chang-qing Xu, Zi-tan Zhang, Zong-jiu Jiao · 2022 · Pakistan Journal of Medical Sciences
  48. The Interaction of Immune System in Tumour Microenvironment and Possible Role of Cancer Cell Immnunosensitization for Better Treatment Efficacy: A Review
    Farhana Khamarudin, Mudiana Muhamad, Jesmine Khan, Mohammad Johari Ibahim, Wan Nor I’zzah Wan Mohamad Zain, Mardiana Abdul Aziz, Nurul Raudzah Adib Ridzuan, Sharaniza Ab Rahim · 2023 · Malaysian Applied Biology
  49. Multiple myeloma in the mandible mimicking a radicular cyst: A case report and literature review
    Yasuyuki Shimada, Hideki Miyazaki, Akira Hangaishi, Yutaka Maruoka · 2024 · Oral Science International
  50. R-spondin(g) to syndecan-1 in myeloma
    Steven Grant · 2018 · Blood
  51. Management of Patients with Difficult-To-Treat Multiple Myeloma
    Joshua Ryan Richter, Karthik Ramasamy, Leo Rasche, Joan Bladé, Sonja Zweegman, Faith E. Davies, Meletios Athanasios Dimopoulos · 2021 · Future Oncology
  52. Prostate Cancer Focal Therapy Has Made Great Strides and the Future Remains Bright
    Thomas James Polascik · 2021 · ONCOLOGY
  53. A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weekly
    Xavier P Leleu, Ajai Chari, Shambavi Richard, Monica Khurana, Akeem Yusuf, Saad Z. Usmani · 2021 · Expert Review of Hematology
  54. Chemotherapie von Tumorerkrankungen
    Michael Freissmuth · 2016 · Springer-Lehrbuch
  55. IMPROVING PRECISION IN THERAPIES FOR HEMATOLOGICAL MALIGNANCIES
    Muntasir Mamun Majumder · 2018 · Työväentutkimus Vuosikirja
  56. Primer Plazma Hücreli Lösemi: Olgu Sunumu
    Si̇nan Demi̇rci̇oğlu, Ali Doğan, Murat ALTINBAŞAK, Cengiz Demır · 2019 · Dicle Medical Journal / Dicle Tip Dergisi
  57. Future prospects of chimeric antigen receptor T‐cell therapy for multiple myeloma
    Carlos Fernández de Larrea, Sham Mailankody, Ola Landgren, Eric L. Smith · 2019 · Advances in Cell and Gene Therapy
  58. Aktuelle medizinisch-onkologische Aspekte der Onkologischen Rehabilitation
    Maximilian Marhold · 2019 · Springer eBooks
  59. A phase II clinical trial of lenalidomide intensification in patients with serologic/asymptomatic progression of multiple myeloma while on lenalidomide maintenance: a tri-state transplant consortium study
    Hani Hassoun, Ruthee L. Bayer, Sean M. Devlin, Theresa Gentile, Michael W. Becker, Kristen O’Dweyer, MARTIN L. LESSER, Heather Jolie Landau, David J. Chung, Sergio Giralt · 2020 · Leukemia & lymphoma/Leukemia and lymphoma
  60. The FYN-TRAF3IP2 gene fusion drives oncogenic NF-κB signaling in peripheral T cell lymphoma
    Christine Sheila Kim · 2019
  61. Biological and Translational Considerations regarding the Recent Therapeutic Successes and Upcoming Challenges for Multiple Myeloma
    Constantine S. Mitsiades · 2020 · Cold Spring Harbor Perspectives in Medicine
  62. Use of Real-World Evidence in Hematology/Oncology Treatment Optimization
    Julie Marie Vose · 2020 · ONCOLOGY
  63. Opening Doors: Fertility Preservation for Adolescents and Young Adults Facing Gonadotoxic Therapy
    Elizabeth Stephens Constance · 2020 · ONCOLOGY
  64. Application and research progress of BCL2 inhibitors in elderly patients with hematologic malignancies
    Yufan Wang, Liang Wang · 2020 · Aging Pathobiology and Therapeutics
  65. Clinical and Immunological Aspects of Pneumococcal Vaccination in Patients with Multiple Myeloma
    И. О. Стома · 2021 · Epidemiology and Vaccinal Prevention
  66. Identification of key genes in relapsed multiple myeloma by weighted gene co-expression network analysis
    Lele Cao, Meng Ye, Rui Huang, Xiaoxue Wang, Hui Qin · 2021 · Research Square
  67. SLAMF7 Regulates Inflammatory Response In Macrophage During Polymicrobial Sepsis
    Yongjian Wu, Juanfeng Lao, Miao Li, Minhao Wu, Siqi Ming, Lei Liu, Sitang Gong, Haibo Zhou, Xi Huang · 2021 · Research Square
  68. Molecular Profiling Practices in Pancreatic Adenocarcinoma: Academic vs Community Physicians
    Christine Chung, Rachael M. Galvin, Ella Achenbach, Oliwier Dziadkowiec, Shiraj Sen · 2021 · ONCOLOGY
  69. Hand-Foot Skin Reaction Secondary to Sunitinib in a Patient With Metastatic Clear Cell Renal Cell Carcinoma
    Karen Férez-Blando, Francisco J. Castro-Alonso, Judith Domínguez‐Cherit, Maria Teresa Bourlon · 2021 · ONCOLOGY
  70. Expanding CD38-targeting triplets for relapsed or refractory multiple myeloma
    Michèle Cavo, Paola Tacchetti, Elena Zamagni · 2021 · The Lancet
  71. A novel human multiple myeloma cell line with genetic abnormality of 1q21 gains only and CKS1B overexpression
    Ke Yi, Hui Zhang, Yajun Zhang, Weijun Fu, Jian Hou, Rong Li · 2020 · Research Square
  72. Plataforma magnética multifuncional de magnetita funcionalizada com diferentes ligantes para aplicações biológicas
    Caio José Perecin · 2021
  73. Myelomatous meningitis: a case report
    Yuriko Aratake, Ryosuke Takaya, Katsuro Shindo · 2021 · Rinsho Shinkeigaku
  74. Indirubin-3’-Monoxime Acts as a Novel Proteasome Inhibitor: Therapeutic Application in Multiple Myeloma
    Zhen Yu, Lanting Liu, Kefei Wang, Hao Sun, Xiaojing We, Weiwei Sui, Teng Fang, Lu Wang, Ying Li, Yaozhong Zhao et al. · 2021 · SSRN Electronic Journal
  75. Immunomodulatory drug and dexamethasone-containing triple versus doublet combination treatments for relapsed or refractory multiple myeloma: a meta-analysis of phase III randomized controlled trials
    Minjie Gao, Xiao Yan, Fei Li, Kaihong Xu, Qitian Mu, Lixia Sheng, Yi Wang, Van S. Tompkins, Guifang Ouyang · 2020
  76. International Society of Gastrointestinal Oncology Conference Abstracts
    Bekaii-Saab,Tanios; · 2020 · ONCOLOGY
  77. Promising Therapies Emerging for Recurrent/Metastatic Cervical Cancer
    2020 · ONCOLOGY
  78. Multiple Myeloma
    Huilan Zeng, Yuhua Li, Dong‐Hua Yang · 2021 · Elsevier eBooks
  79. Hitting a New Target in Multiple Myeloma
    2020 · ONCOLOGY
  80. Treatment of relapsed and refractory multiple myeloma
    Denisa Nováková, Jakub Radocha · 2021 · Onkologie
  81. Development of a 3D in Vitro Disease Model for Multiple Myeloma
    Sandra Clara Trujillo · 2022 · RiuNet (Universitat Politècnica de València)
  82. Multiple Myeloma in the Era of Novel Agents and Stem Cell Therapies
    Khalid Ahmed Al‐Anazi · 2023 · IntechOpen eBooks
  83. Pan-cancer analysis of co-inhibitory molecules reveals their potential prognostic and clinical values as biomarkers
    Xiaoyu Ren, Jiahui Geng, Yuling Chen, Xue Wang, Lian Zhou, Lei Shi · 2023 · Research Square
  84. Data from Adaptive Natural Killer Cells Facilitate Effector Functions of Daratumumab in Multiple Myeloma
    Hyunsoo Cho, Kyung Hwan Kim, Hoyoung Lee, Chang Gon Kim, Haerim Chung, Yoon Seok Choi, Su‐Hyung Park, June‐Won Cheong, Yoo Hong Min, Eui‐Cheol Shin et al. · 2023
  85. Data from Adaptive Natural Killer Cells Facilitate Effector Functions of Daratumumab in Multiple Myeloma
    Hyunsoo Cho, Kyung Hwan Kim, Hoyoung Lee, Chang Gon Kim, Haerim Chung, Yoon Seok Choi, Su‐Hyung Park, June‐Won Cheong, Yoo Hong Min, Eui‐Cheol Shin et al. · 2023
  86. Data from Lenalidomide Augments the Antitumor Activities of Eps8 Peptide-Specific Cytotoxic T Lymphocytes against Multiple Myeloma
    Xiaoling Xie, Yiran Chen, Yuxing Hu, Yanjie He, Honghao Zhang, Yuhua Li · 2023
  87. Use of CAR-T cells for the treatment of relapsed and refractory multiple myeloma: a systematic review
    Satchie Sakamoto, Vanessa Sgnaolin · 2024 · Brazilian Journal of Oncology
  88. Advances in the Treatment of Extramedullary Multiple Myeloma
    鹏慧 任 · 2024 · Journal of Clinical Personalized Medicine
  89. Expert Opinion on Multiple Myeloma Treatment in Brazil in the Bispecific Antibody Era
    Vânia Hungria, Jorge Vaz Pinto Neto, Pedro Manoel Marques Garibaldi, Angela Marie Jansen, Roberto Josè Pessoa de Magalhães Filho, Fernando Vieira Pericole, Gayatri Sanku, Ângelo Maiolino · 2024 · Clinical Lymphoma Myeloma & Leukemia
  90. Bortezomib, Mitoxantrone Hydrochloride Liposome, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Multi‐Center, Open‐Label Phase I Trial
    Ya‐Lan Zhou, Jinqiao Zhang, Wei Wang, Li Bao, Bai‐Jun Fang, Da Gao, Liping Su, Wenming Chen, Guangzhong Yang · 2025 · Cancer Medicine
  91. Combination Therapies in Drug Repurposing: Personalized Approaches to Combatting Leukaemia and Multiple Myeloma
    Bernice A. Monchusi, P. Dube, Mutsa Monica Takundwa, Vanelle Larissa Kenmogne, Thudzelani Takalani Austin Malise, Deepak B. Thimiri Govinda Raj · 2025 · Advances in experimental medicine and biology
  92. Advanced Multicolor Flow Cytometry Method for Multiple Myeloma
    Noa Ofir, Ety Rozenberg, Omri Sharabi, Miri Zektser, Ory Rouvio, Roi Gazit · 2025 · Clinical Lymphoma Myeloma & Leukemia
  93. The impact of STAiR18 on multiple myeloma survival rates
    Yingmiao Wu, Haolin Wang, Ji Luo, Jiaoya Lin, Yajie Wu, Shuai Zheng, Yifei Gao, Jiao Chen, Feifei Che, Jianyou Shi et al. · 2025 · Journal of Translational Medicine
  94. Additional file 1 of PD-1 and LAG-3-positive T cells are associated with clinical outcomes of relapsed/refractory multiple myeloma patients
    Chen, Ming, Zhu, Jinlian, Yang, Xuedong, Yao, Jianxin, Liu, Yuqing, Liu, Qiang · 2024 · Figshare
  95. PET imaging of XPO1 engagement with [18F]selinexor: A pharmacodynamic theranostic strategy for multiple myeloma
    Xinlin Zhong, Lizhen Wang, Junjie Yan, Chen Su, Xinyu Wang, Donghui Pan, Yuping Xu, Chongyang Chen, Min Yang · 2026 · Bioorganic Chemistry
  96. CD138-targeted bispecific protein engager-armed T cells exhibit potent and selective cytotoxicity against multiple myeloma cells
    Pucharee Songprakhon, Piriya Luangwattananun, Kornkan Choomee, Nunghathai Sawasdee, Chalermchai Somboonpatarakun, Thaweesak Chieochansin, Sanya Sukpanichnant, Mutita Junking, Seiji Okada, Pa‐thai Yenchitsomanus · 2026 · International Immunopharmacology
  97. Improved outcomes in relapsed and refractory multiple myeloma: a single-center real-world analysis of evolving treatment standards
    Vincent Luong, Muhammad Kashif, Katarina Uttervall, Hazel Reilly, Anna Bohlin, Nurşen Çetrez, Johan Lund, Hareth Nahi, Evren Alici, Gabriel Afram · 2026 · Central European Journal of Immunology
  98. Etude de l'implication de mécanismes épigénétiques dans la physiopathologie du myélome multiple et dans la différenciation plasmocytaire normale
    Laurie Herviou · 2018 · theses.fr (ABES)
  99. Développement et évaluation d'anticorps bispécifiques dans le traitement du Myélome multiple
    Maxime Fayon · 2019 · theses.fr (ABES)
  100. Exploration des récepteurs à dépendance dans les hémopathies malignes
    David Fahed · 2020 · theses.fr (ABES)